Table 1 Clinical characteristics of full cohort and the two treatment groups
Clinical characteristics | Overall | SIB | Brachy | p value |
|---|---|---|---|---|
Number (%) | ||||
All subjects | 243 | 110 | 133 | Â |
HPV-status | Â | Â | Â | 0.610 |
 Negative | 34 (14.0) | 14 (12.7) | 20 (15.0) |  |
 Positive | 205 (84.4) | 95 (86.4) | 110 (82.7) |  |
 Unknown | 4 (1.6) | 1 (0.9) | 3 (2.3) |  |
Age | Â | Â | Â | 0.223 |
  > Median (62 years) | 122 (50.2) | 50 (45.5) | 72 (54.1) |  |
  ≤ Median (62 years) | 121 (49.8) | 60 (54.5) | 61 (45.9) |  |
Tumour stage* | Â | Â | Â | 0.389 |
 I-II | 17 (7.0) | 5 (4.5) | 12 (9.0) |  |
 III | 29 (11.9) | 13 (11.8) | 16 (12.0) |  |
 IV | 197 (81.1) | 92 (83.6) | 105 (78.9) |  |
T stage |  |  |  |  < 0.001 |
 1 | 32 (13.2) | 3 (2.7) | 29 (21.8) |  |
 2 | 72 (29.6) | 28 (25.5) | 44 (33.1) |  |
 3 | 71 (29.2) | 39 (35.5) | 32 (24.1) |  |
 4 | 68 (28.0) | 40 (36.4) | 28 (21.1) |  |
Tumour site |  |  |  |  < 0.001 |
 Base of tongue | 134 (55.1) | 42 (38.2) | 92 (69.2) |  |
 Tonsil | 102 (42.0) | 64 (58.2) | 38 (28.6) |  |
 Other†| 7 (2.9) | 4 (3.6) | 3 (2.3) |  |
Performance status (PS) | Â | Â | Â | 0.359 |
 PS 0 | 208 (85.6) | 96 (87.3) | 112 (84.2) |  |
 PS 1 | 29 (11.9) | 13 (11.8) | 16 (12.0) |  |
 PS 2 | 6 (2.5) | 1 (0.9) | 5 (3.8) |  |
Gender | Â | Â | Â | 0.963 |
 Male | 187 (77.0) | 84 (76.4) | 103 (77.4) |  |
 Female | 56 (23.0) | 26 (23.6) | 30 (22.6) |  |
Concurrent medical treatment | Â | Â | Â | 0.042 |
 Cetuximab | 111 (45.7) | 51 (46.4) | 60 (45.1) |  |
 Cetuximab + Cisplatin | 9 (3.7) | 5 (4.5) | 4 (3.0) |  |
 Cisplatin | 74 (30.5) | 40 (36.4) | 34 (25.6) |  |
 None | 49 (20.2) | 14 (12.7) | 35 (26.3) |  |
Induction chemotherapy |  |  |  |  < 0.001 |
 Yes | 93 (38.3) | 27 (24.5) | 66 (49.6) |  |
 No | 150 (61.7) | 83 (75.5) | 67 (50.4) |  |
Medical treatment (concurrent or induction) | Â | Â | Â | 0.944 |
 Yes | 215 (88.5) | 98 (90.1) | 117 (88.0) |  |
 No | 28 (11.5) | 12 (10.9) | 16 (12.0) |  |
Cisplatin containing medical treatment | Â | Â | Â | 0.069 |
 Yes | 151 (62.1) | 61 (55.5) | 90 (67.7) |  |
 No | 92 (37.9) | 49 (44.5) | 43 (32.3) |  |
Smoking status at start of radiotherapy | Â | Â | Â | 0.861 |
 Never | 84 (34.6) | 40 (36.4) | 44 (33.1) |  |
 Current | 53 (21.8) | 23 (20.9) | 30 (22.6) |  |
 Former | 106 (43.6) | 47 (42.7) | 59 (44.4) |  |
Recurrence | Â | Â | Â | 0.212 |
 No recurrence | 193 (79.4) | 87 (79.1) | 106 (79.7) |  |
 Local recurrence | 25 (10.3) | 11 (10.0) | 14 (10.5) |  |
 Regional recurrence | 4 (1.6) | 0 (0.0) | 4 (3.0) |  |
 Distant metastasis | 10 (4.1) | 5 (4.5) | 5 (3.8) |  |
 Distant metastasis + local/regional recurrence | 8 (3.3) | 4 (3.6) | 4 (3.0) |  |
 Cannot be assessed | 3 (1.2) | 3 (2.7) | 0 (0.0) |  |